Carbapenem-Resistant Klebsiella pneumoniae Among Patients with Ventilator-Associated Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics

References

• Pozuelo-Carrascosa DP, Cobo-Cuenca AI, Carmona-Torres JM, Laredo-Aguilera JA, Santacruz-Salas E, Fernandez-Rodriguez R. Body position for preventing ventilator-associated pneumonia for critically ill patients: a systematic review and network meta-analysis. J Intensive Care. 2022;10(1):9. doi:10.1186/s40560-022-00600-z
   PubMed Web of Science ®Google Scholar
• Erfani Y, Rasti A, Janani L. Prevalence of Gram negative bacteria in ventilator-associated pneumonia in neonatal intensive care units: a systematic review and meta-analysis protocol. BMJ Open. 2016;6(10):e012298. doi:10.1136/bmjopen-2016-012298
   Web of Science ®Google Scholar
• Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Mirobiol. 2010;13(5):558–564. doi:10.1136/bmjopen-2016-012298
   PubMed Web of Science ®Google Scholar
• El-Herte R, Kanj S, Matar G, Araj G. The threat of carbapenem resistant Enterobacteriaceae in Lebanon: an update on the regional and local epidemiology. J Infect Public Health. 2012;5(3):233–243. doi:10.1016/j.jiph.2012.02.003
   PubMedGoogle Scholar
• Laishram S, Pragasam AK, Bakthavatchalam YD, Veeraraghavan B. An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies. Indian J of Med Microbiol. 2017;35(4):445–468. doi:10.4103/ijmm.IJMM_17_189
   PubMed Web of Science ®Google Scholar
• Barbier F, Bailly S, Schwebel C, et al. Infection-related ventilator-associated complications in ICU patients colonized with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Intensive Care Med. 2018;44(5):616–626. doi:10.1007/s00134-018-5154-4
   Web of Science ®Google Scholar
• Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10(8):917–934. doi:10.1586/eri.12.78
   PubMed Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–575. doi:10.1093/cid/ciz830
   PubMed Web of Science ®Google Scholar
• Magill SS, Klompas M, Balk R, et al. Developing a new, national approach to surveillance for ventilator-associated events: executive summary. Clin Infect Dis. 2013;57(12):1742–1746. doi:10.1093/cid/cit577
   Web of Science ®Google Scholar
• Azzab MM, El Sokkary RH, Tawfeek MM, Gebriel MG. Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt. EMHJ. 2016;22(12):894–903. doi:10.26719/2016.22.12.894
   Web of Science ®Google Scholar
• Wu CL, Yang DI, Wang NY, Kuo HT, Chen PZ. Quantitative culture of endotracheal aspirates in the diagnosis of ventilator associated pneumonia in patients with treatment failure. Chest. 2002;122:662–668. doi:10.1378/chest.122.2.662
   Web of Science ®Google Scholar
• Cheesbrough M. District Laboratory Practice in Tropical Countries: Part 2. 1st ed. Cambridge University Press; 2006:62–70.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. CLSI supplement M100. Wayne, PA: Clinical and LaboratoryStandards Institute; 2021.
   Google Scholar
• Magiorakos A-P, Srinivasan A, Carey R, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–123. doi:10.1016/j.diagmicrobio.2010.12.002
   PubMed Web of Science ®Google Scholar
• Sueke H, Kaye SB, Neal T, Hall A, Tuft S, Parry CM. An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51(8):4151–4155. doi:10.1167/iovs.09-4839
   PubMed Web of Science ®Google Scholar
• Pillai SK, Moellering RC, Eliopoulos GM. Antibiotics in laboratory medicine. In: Lorian V, editor. Antibiotics in Laboratory Medicine. 5th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2005:365–440.
   Google Scholar
• El-Kholy A, Saied T, Gaber M, et al. Device-associated nosocomial infection rates in intensive care units at Cairo University hospitals: the first step toward initiating surveillance programs in a resource-limited country. Am J Infect Control. 2012;40(6):e216–e220. doi:10.1016/j.ajic.2011.12.010
   Web of Science ®Google Scholar
• Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46(5):888–906. doi:10.1007/s00134-020-05980-0
   PubMed Web of Science ®Google Scholar
• Negm EM, Mowafy S, Mohammed AA, et al. Antibiograms of intensive care units at an Egyptian tertiary care hospital. Egypt J Bronchol. 2021;15(1):1–5. doi:10.1186/s43168-021-00059-w
   Google Scholar
• Qadeer A, Akhtar A, Ain QU, et al. Antibiogram of medical intensive care unit at tertiary care hospital setting of Pakistan. Cureus. 2016;8(9):e809. doi:10.7759/cureus.809
   Google Scholar
• Gunjal P, Gunjal S, Kher S. A cross-sectional study to determine the profile and antibiotic resistance pattern of Gram-negative bacilli isolated from intensive care unit patients in a tertiary care hospital in Ahmednagar, Maharastra. Int J Biomed Adv Res. 2012;3(5):281–284. doi:10.7759/cureus.809
   Google Scholar
• Zafer MM, El-Mahallawy HA, Abdulhak A, Amin MA, Al-Agamy MH, Radwan HH. Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients. Ann Clin Microbiol Antimicrob. 2019;18(1):40. doi:10.1186/s12941-019-0339-4
   PubMed Web of Science ®Google Scholar
• Patro S, Sarangi G, Das P, et al. Bacteriological profile of ventilator-associated pneumonia in a tertiary care hospital. Indian J Pathol Microbio. 2018;61(3):375–379. doi:10.4103/IJPM.IJPM_487_16
   Web of Science ®Google Scholar
• Muhammed M, Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Comparison between carbapenems and β-Lactam/β-Lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum β-Lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. Open Forum Infect Dis. 2017;4(2):ofx099. doi:10.1093/ofid/ofx099
   PubMed Web of Science ®Google Scholar
• Toubiana J, Timsit S, Ferroni A, et al. Community-onset extended-spectrum β-Lactamase- producing Enterobacteriaceae invasive infections in children in a university hospital in France. Medicine. 2016;95(12):e3163. doi:10.1097/MD.0000000000003163
   Web of Science ®Google Scholar
• El-Sokkary RH, Negm EM, Othman HA, Tawfeek MM, Metwally WS. Stewardship actions for device associated infections: an intervention study in the emergency intensive care unit. J Infect Public Health. 2020;13(12):1927–1931. doi:10.1016/j.jiph.2020.10.003
   Web of Science ®Google Scholar
• Raheel A, Azab H, Hessam W, Abbadi S, Ezzat A. Detection of carbapenemase enzymes and genes among carbapenem-resistant Enterobacteriaceae isolates in Suez Canal University Hospitals in Ismailia, Egypt. Microbes Infect Dis. 2020;1(1):24–33. doi:10.21608/mid.2020.25702.1007
   Google Scholar
• Mohamed ER, Ali MY, Waly NG, Halby HM, El-Baky RMA. The Inc FII plasmid and its contribution in the transmission of blaNDM-1 and blaKPC-2 in Klebsiella pneumoniae in Egypt. Antibiotics. 2019;8(4):266. doi:10.3390/antibiotics8040266
   Google Scholar
• Ahmed El-Domany R, El-Banna T, Sonbol F, Abu-Sayedahmed SH. Co-existence of NDM-1 and OXA-48 genes in carbapenem resistant Klebsiella pneumoniae clinical isolates in Kafrelsheikh, Egypt. Afr Health Sci. 2021;21(2):489–496. doi:10.4314/ahs.v21i2.2
   Web of Science ®Google Scholar
• Tawfick MM, Alshareef WA, Bendary HA, Elmahalawy H, Abdulall AK. The emergence of carbapenemase blaNDM genotype among carbapenem-resistant Enterobacteriaceae isolates from Egyptian cancer patients. Eur J Clin Microbiol Infect Dis. 2020;39(7):1251–1259. doi:10.1007/s10096-020-03839-2
   Web of Science ®Google Scholar
• Baran I, Aksu N. Phenotypic and genotypic characteristics of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Turkey. Ann Clin Microbiol Antimicrob. 2016;15:20. doi:10.1186/s12941-016-0136-2
   Web of Science ®Google Scholar
• Codjoe FS, Donkor ES. Carbapenem resistance: a review. Med Sci. 2018;6(1):1. doi:10.3390/medsci6010001
   Google Scholar
• El-Kholy AA, Elanany MG, Sherif MM, Gad MA. High prevalence of VIM, KPC, and NDM expression among surgical site infection pathogens in patients having emergency surgery. Surg Infect (Larchmt). 2018;19(6):629–633. doi:10.1089/sur.2018.088
   Web of Science ®Google Scholar
• Xie L, Dou Y, Zhou K, et al. Coexistence of blaOXA−48 and truncated blaNDM−1 on different plasmids in a Klebsiella pneumoniae isolate in China. Front Microbiol. 2017;8:133. doi:10.3389/fmicb.2017.00133
   Web of Science ®Google Scholar
• Karki R, Lamichhane S, Basnet BB, Dahal A, Awal BK, Mishra SK. In vitro antimicrobial synergy testing of extensively drug-resistant clinical isolates at an organ transplant center in Nepal. Infect Drug Resist. 2021;14:1669–1677. doi:10.2147/IDR.S309531
   Web of Science ®Google Scholar
• Dhandapani S, Sistla S, Gunalan A, Manoharan M, Sugumar M, Sastry AS. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E. coli and Klebsiella pneumoniae by checkerboard method. Indian J Med Microbiol. 2021;39(1):6–10. doi:10.1016/j.ijmmb.2020.10.018
   Web of Science ®Google Scholar
• Liao CH, Lee NY, Tang HJ, et al. Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the surveillance of multicenter antimicrobial resistance in Taiwan in 2016. Infect Drug Resist. 2019;12:545–552. doi:10.2147/IDR.S193638
   Web of Science ®Google Scholar
• de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In vitro susceptibility to ceftazidime-avibactam of carbapenem non susceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother. 2016;60(5):3163–3169. doi:10.1128/AAC.03042-15
   PubMed Web of Science ®Google Scholar
• Sharma R, Park TE, Moy S. Ceftazidime-avibactam: a novel cephalosporin/βlactamase inhibitor combination for the treatment of resistant Gram-negative organisms. Clin Ther. 2016;38:431–444. doi:10.1016/j.clinthera.2016.01.018
   PubMed Web of Science ®Google Scholar
• Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L. The revival of aztreonam in combination with avibactam against metallo-β-Lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases. Antibiotics. 2021;10:1012. doi:10.3390/antibiotics10081012
   Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e183. PMID: 33106864. doi:10.1093/cid/ciaa1478
   PubMed Web of Science ®Google Scholar
• Iregui A, Khan Z, Landman D, Quale J. Activity of cefiderocol against enterobacterales, pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York city. Microb Drug Resist. 2020;26(7):722–726. doi:10.1089/mdr.2019.0298
   Web of Science ®Google Scholar
• Hobson CA, Cointe A, Jacquier H, et al. Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect. Clin Microbiol Infect. 2021;27(8):1172.e7–1172.e10. doi:10.1016/j.cmi.2021.04.016
   PubMed Web of Science ®Google Scholar
• Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S544–S551. doi:10.1093/cid/ciz827
   PubMed Web of Science ®Google Scholar